Making top-quality cancer care accessible to all.100% free, no account required.

Treating Melanoma with Brain Metastases: Comparing Two Treatment Options

NCT04511013 · Recruiting
About this trial

This trial looks at two different treatment options for patients with a type of skin cancer called melanoma that has spread to the brain. One treatment combines three medicines, while the other uses two. The goal is to see which combination works better at shrinking tumors and controlling growth in the brain.

Locations and contact

This trial is running at 331 locations. The first 8 are listed here.

  • University of Alabama at Birmingham Cancer CenterBirmingham, AlabamaRecruiting
  • Thomas HospitalFairhope, AlabamaRecruiting
  • Mobile Infirmary Medical CenterMobile, AlabamaRecruiting
  • Anchorage Associates in Radiation MedicineAnchorage, AlaskaRecruiting
  • Anchorage Radiation Therapy CenterAnchorage, AlaskaRecruiting
  • Alaska Breast Care and Surgery LLCAnchorage, AlaskaRecruiting
  • Alaska Oncology and Hematology LLCAnchorage, AlaskaRecruiting
  • Alaska Women's Cancer CareAnchorage, AlaskaRecruiting
See all 331 locations →
Who to ask about joining
Who can join

The trial is for adults aged 18 and older, both men and women. Participants must have melanoma that has spread to the brain and have a specific mutation called BRAF-V600. Some other health conditions may affect eligibility, but the trial team will confirm who can join.

What happens during the trial

Participants will be placed into one of two groups by chance. One group will receive a combination of three medicines: encorafenib, binimetinib, and nivolumab. The other group will get nivolumab and ipilimumab. Treatments are given for several weeks, and everyone will be followed closely to see how well the treatments work.

The trial team

The trial is led by the SWOG Cancer Research Network with support from the National Cancer Institute. Dr. Zeynep Eroglu is the principal investigator overseeing the study.

Important dates

The trial started on January 6, 2021, and is expected to finish on June 30, 2027. It is currently enrolling new participants.

Additional information

This is a Phase 2 trial, which means it is looking at how well the treatments work and how safe they are. The trial is regulated by the FDA and aims to include about 112 participants.

Similar trials

Other recruiting trials for the same condition, with the eligibility rules written in plain language.

Browse similar trials
Talk to a specialist

Find a top oncologist who can tell you whether a trial is a sensible option for you.

Find a doctor
Cancer hospitals

The cancer centers running studies like this one, and what each is known for.

Browse hospitals
Treating Melanoma with Brain Metastases: Comparing Two…